Peptide profiler
Quick adme quote
Connect with us
TRILLIONS OF COMPOUNDS SCREENED - ONLY PAY FOR QUALIFIED HITS
Partnering with OpenBench for fee-for-success drug discovery
Accelerate your path from target to validated hits, without upfront cost or risk. Our strategic partnership with OpenBench combines AI-driven discovery with our integrated drug discovery platform to deliver derisked hit generation and screening in as little as six months. With a success-based model, you only pay for qualified hits, providing an efficient and lower risk approach to advance your programs in today's challenging funding environment.
A faster, lower risk path to high quality hits
Traditional hit discovery is slow, capital intensive, and uncertain. Biotech teams are under pressure to advance pipelines faster, with fewer resources, and less tolerance for risk, often requiring significant upfront investment, without the guarantee of success.
Designed for early-stage biotech, our partnership removes early-stage obstacles by providing a new path: high-quality, developable chemical starting points, delivered through a model built for today’s funding environment.
We deliver a developable hit series, not just predictions, enabling you to advance your projects with confidence in the return on your investment.
Focus resources on proven programs and de-risk pipeline development decisions
Seamless progression into lead optimization with Concept Life Sciences integrated discovery platform
No upfront discovery cost, only pay for validated hits
